Krystal Biotech, Inc. KRYS 深 滬
等待開盤 07-21 09:30:00 美东时间
147.49
-2.660
-1.77%
華盛通- 最 高152.2475
- 今 開151.33
- 成交量 30.41万股
- 最 低 146.35
- 昨 收 150.15
- 總市值 42.62亿
- 52周最高 213.52
- 市盈率 靜 49.20
- 換手率 0.00%
- 52周最低 122.80
- 委 比 -63.83%
- 總股本 2889.87万
- 歷史最高 219.34
- 量 比 1.08
- 振 幅 3.93%
- 歷史最低 8.03
- 每 手 1
- 風險率 33.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Citigroup Maintains Neutral on Krystal Biotech, Raises Price Target to $176
Citigroup analyst Carly Kenselaar maintains Krystal Biotech (NASDAQ:KRYS) with a Neutral and raises the price target from $155 to $176.
07-11 05:09
Krystal Biotech Has Dosed The First Patient In Its Phase 1/2 EMERALD-1 Trial Evaluating KB801 For Neurotrophic Keratitis
KB801 is a redosable eye drop gene therapy in development for the treatment of NK, a degenerative corneal disease characterized by damage or loss of function in the neurons innervating the eye leading to corneal
07-09 19:04
Abeona sells Rare Pediatric Disease PRV for $155M
Shares of Abeona Therapeutics (NASDAQ:ABEO) rose on Wednesday after the company said that it has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV), earning $155M on June 2...
07-02 23:47
Peering Into Krystal Biotech's Recent Short Interest
Krystal Biotech's (NYSE:KRYS) short percent of float has risen 3.83% since its ...
07-02 23:00
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
Clear Street Initiates Coverage On Krystal Biotech with Buy Rating, Announces Price Target of $190
Clear Street analyst Bill Maughan initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Buy rating and announces Price Target of $190.
07-01 21:50
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Demystifying Krystal Biotech: Insights From 7 Analyst Reviews
Across the recent three months, 7 analysts have shared their insights on Krysta...
06-25 05:00
Krystal Biotech Begins Late-Stage Trial for Eye Treatment Aimed at Preventing Vision Loss in Rare Skin Disease
Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the first patient has been dosed in its Phase 3 clinical trial ("IOLITE"), an intra-patient, double-blind, multicenter, placebo-controlled study
06-24 19:06
